PRESS RELEASE

Munich, 12 September 2024

The CERTANIA Group is a strategic investor in Testing, Inspection, Certification and Research (TIC) with the goal of building a network of leading companies that contribute to health and sustainability in operations and their ecosystems. This is based on companies that combine in-depth expertise with outstanding customer service to create a winning formula. In the CERTANIA Group, their competencies are brought together to create holistic solutions and serve customers along the entire value chain. CERTANIA Holding has a long-term investment plan around successful partnerships with management teams, with the goal of jointly building a leading TIC group. The partners of the CERTANIA Group maintain a strong independence and preserve their entrepreneurial drive. Through their partnership within the CERTANIA Group, they will have the opportunity to combine and jointly develop their expertise from different TIC sectors to meet the ever-growing consumer need for transparency and verification in health and sustainability – while maintaining their identity.

Founded in 1995 and headquartered in Berlin, Germany, Alphalytik has built a strong reputation as an independent laboratory specializing in GMP (Good Manufacturing Practice) and FDA (Food and Drug Administration) approved stability testing, method development, and release testing. With a focus on complex drug formulations, including low-dose and hormone preparations, Alphalytik serves a diverse clientele, including some of the world’s leading pharmaceutical companies. The company’s expertise in ensuring the long-term safety and efficacy of pharmaceutical products has made it a trusted partner.

Both sides have agreed not to disclose details of the transactions.

ADVISORS CERTANIA Group:

honert (Munich): Patrick Spalek (lead), Arik Widenhorn, Felix Strobel (all corporate law, M&A)